Overview of Etosys-MF

Property	Description
Active Ingredients	Mefenamic Acid, Tranexamic Acid
Form	Fixed-dose combination (FDC) oral tablet
Pharmacological Class	Non-Steroidal Anti-Inflammatory Drug (NSAID) and Antifibrinolytic
General Purpose	Simultaneous pain relief and bleeding control
Origin	Synthetic compound

Etosys-MF: Identity and Pharmacological Classification

Etosys-MF is a Prescription-only medicine administered as a fixed-dose combination (FDC) oral tablet, which functions as a Dual-Action Agent. Its pharmacological classification combines the attributes of two distinct therapeutic categories: a Non-Steroidal Anti-Inflammatory Drug (NSAID) and an Antifibrinolytic agent. This integrated structure is clinically recognized for addressing conditions where pain and bleeding coexist.

The product's identity is defined by its two active compounds. Mefenamic Acid classifies its analgesic component as an Anthranilic Acid derivative, while Tranexamic Acid is recognized for its role in preventing the dissolution of blood clots, classified as an Antifibrinolytic Agent.

Composition and Origin: Unique Features of the Combination

The formulation relies on the two primary active ingredients by International Nonproprietary Name (INN): Mefenamic Acid and Tranexamic Acid. Both are confirmed synthetic compounds.

The inclusion of the Mefenamic Acid component serves as the analgesic component, mitigating pain and inflammation, while Tranexamic Acid acts as the hemostatic component, supporting clot stabilization. The therapeutic utility of combining these two distinct pharmacological actions for managing excessive blood flow is recognized. This formulation is differentiated by its explicit positioning for integrated management.

What side effects are possible with Etosys-MF?

Possible Side Effects and Safety Information for Etosys-MF

Serious Warnings and Contraindications

This medication contains an NSAID component which carries an official regulatory Boxed Warning regarding the risk of serious cardiovascular and gastrointestinal adverse events. The risk of fatal cardiovascular thrombotic events (including heart attack and stroke) and severe gastrointestinal bleeding, ulceration, or perforation may increase with duration of use and in patients with pre-existing risk factors. The drug is contraindicated for treating peri-operative pain after coronary artery bypass graft (CABG) surgery.

Due to the antifibrinolytic component, the drug is also contraindicated in patients with active intravascular clotting, a history of thrombosis, or known defective color vision. The use of combined hormonal contraceptives is contraindicated while taking this medication due to a potentially heightened risk of venous and arterial thrombotic events, especially in women over 35 who smoke.

Common and Clinically Significant Adverse Reactions

Common adverse reactions typically involve the gastrointestinal system (e.g., diarrhea, nausea, vomiting, abdominal pain) and the nervous system (e.g., headache, dizziness). Musculoskeletal pain and sinonasal symptoms are also frequently reported.

Serious or clinically significant reactions reported in regulatory documents include seizures, severe hypersensitivity reactions (including anaphylaxis), and severe cutaneous adverse reactions (e.g., Stevens-Johnson Syndrome). Patients must be instructed to monitor for visual disturbances or changes in color vision, as treatment should be discontinued immediately for ophthalmic evaluation due to the risk of retinal occlusion.

Special Safety Considerations

Patients with severe kidney, liver, or heart failure should not use this drug. It is not recommended for use in children under 14 years of age. Due to the risk of dizziness or blurred vision, caution is advised when operating machinery. The concurrent use of other systemic NSAIDs or alcohol should be avoided due to the increased risk of gastrointestinal bleeding.

Overdose and Emergency Response

Overdose and When to Seek Help

If you suspect an overdose of Etosys-MF (a combination of Tranexamic Acid and Mefenamic Acid), you must seek immediate medical attention by contacting emergency services or going to the nearest hospital, even if you feel well.

Official regulatory information describes specific manifestations that may occur in a suspected overdose, requiring immediate professional assessment.

Documented Overdose Presentations
Gastrointestinal: Nausea, Vomiting, Diarrhoea
Neurological: Dizziness, Headache, Convulsions (Fits)
Vascular: Fall in Blood Pressure (Hypotension)

Serious risks associated with overdosage include the potential for generalized convulsions/fits and an increased risk of thromboembolic events (blood clots), due to the effect of one of the active components. These are considered severe outcomes that require urgent medical intervention and monitoring.

Management and Emergency Response

There is no specific antidote listed for an Etosys-MF overdose. Management is supportive and symptomatic, with professional care often including clinical monitoring and procedures such as gastric decontamination (e.g., stomach lavage or activated charcoal) to limit absorption. Maintaining adequate fluid intake may also be initiated to promote the clearance of the drug. The decision to initiate anticoagulant treatment may be considered in predisposed individuals due to the reported thromboembolic risk.

Therapeutic Uses of Etosys-MF

The combination of Mefenamic Acid (NSAID) and Tranexamic Acid (antifibrinolytic) is generally used in gynaecology to manage the co-occurrence of symptoms related to both heavy menstrual bleeding and acute menstrual pain. This formulation is commonly applied across domains where additional symptomatic support is needed.

Etosys-MF is relevant in contexts marked by increased discomfort and tension as it is applied in addressing symptom clusters that may become intense or disruptive. The medication is applied in addressing conditions characterized by periods of heightened symptoms, including abnormally heavy or prolonged menstrual bleeding (menorrhagia) and severe menstrual cramps (dysmenorrhea). The medication is recognized as applicable in addressing conditions that present with heavy menstrual bleeding. It plays a role in managing symptoms that interfere with daily comfort by easing acute pain and assisting with managing the symptom burden associated with blood loss, which supports general well-being during symptomatic phases.

Symptomatic Support This combination helps manage the co-occurrence of excessive flow and acute pain symptoms within a single treatment, assisting patients with maintaining functional stability when both types of discomfort interfere with routine activities.

“It is relevant when supportive symptom management is appropriate for two distinct yet co-occurring symptoms, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations during difficult episodes.”

Regulatory References

NIH MedlinePlus overview of Tranexamic Acid

Eligibility and Restrictions for Use

This information describes official regulatory rules regarding eligibility and mandatory restrictions for the use of Etosys-MF (Mefenamic Acid and Tranexamic Acid combination).

Contraindicated (Must Not Use) Populations

Use of Etosys-MF is strictly contraindicated for patients with:

A known allergy or hypersensitivity to mefenamic acid, tranexamic acid, or any other component.
A history of or current thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, cerebral thrombosis, or retinal vein occlusion).
Active intravascular clotting (blood clots forming in the circulatory system).
A history of bleeding in the brain (subarachnoid hemorrhage).
Acquired defective color vision or other significant ocular disorders.
Current or recent Coronary Artery Bypass Graft (CABG) surgery.
Severe kidney disease or significantly impaired renal function.

Age and Physiological Restrictions

Pediatrics: The medicine is generally not recommended for children under 12, 14, or 18 years of age (depending on the specific regulatory source), as safety and effectiveness have not been established in these groups.
Pregnancy: It is generally contraindicated during pregnancy, especially in the last trimester, due to the potential risk of harm to the fetus and complications during labor.
Lactation: Use is contraindicated or not recommended for women who are breastfeeding.

Use with Caution/Special Consideration

Caution is required in patients with a history of epilepsy or convulsions, or those with a history of stomach or intestinal bleeding or ulcers, due to the components in the medicine. Patients using combination hormonal contraceptives face an increased risk of blood clots and should only use this medicine after careful medical review. Dose adjustments are typically needed for patients with non-severe kidney impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Etosys-MF (Mefenamic Acid and Tranexamic Acid) around two primary concerns: additive bleeding risk from the NSAID component and additive thrombotic risk from the antifibrinolytic component.

Contraindicated Combinations

Co-administration is formally contraindicated with other antifibrinolytic agents due to the risk of additive effects. Use is also restricted with Combined Hormonal Contraceptives (containing Estrogens or Progestins) due to the documented risk of thromboembolic events. Furthermore, the Mefenamic Acid component formally prohibits the use of this medication for peri-operative pain in the context of Coronary Artery Bypass Graft (CABG) surgery.

Clinically Significant Interaction Patterns

Interaction Type	Interacting Substances (Examples)	Official Outcome
Increased Bleeding Risk	Warfarin, Heparin, Antiplatelet agents, SSRIs, Corticosteroids	Pharmacodynamic interaction; increased risk of serious gastrointestinal bleeding.
Exposure Modification	Lithium, Methotrexate	Reduced renal clearance of the co-administered drug, leading to increased plasma concentrations and potential toxicity.
Reduced Efficacy	Diuretics, ACE Inhibitors, ARBs	Mefenamic Acid component may diminish the natriuretic and antihypertensive effects of these medicines.
Drug-Substance	Alcohol	Increased risk of serious gastrointestinal adverse events, including ulceration and bleeding.

These interactions may be heightened in elderly patients and individuals with renal or hepatic impairment, necessitating consideration based on official labeling.

Mechanism of Action

How Etosys-MF Works: Mechanism of Action

The Mefenamic Acid component engages in non-selective competitive inhibition of the Cyclooxygenase (COX-1 and COX-2) enzymes. This action centrally prevents the biosynthesis of Prostaglandins (PGs), which function as lipid mediators in the processes of nociceptor sensitization and tissue-level inflammatory signaling. The mechanism results in the functional attenuation of nociceptive signaling and local tissue responsiveness mediated by Prostaglandins.

The second core mechanistic domain involves Tranexamic Acid, a Lysine analog. It functions by occupying the Lysine-Binding Sites (LBS) on the Plasminogen molecule, thereby blocking the enzyme's ability to dock onto the Fibrin matrix of a blood clot . This strategic interference prevents the activation of Plasmin and the subsequent degradation of the Fibrin scaffold, functionally resulting in the preservation of the hemostatic plug structure.

The components exhibit functional complementarity in their mechanisms. Mefenamic Acid limits the synthesis of Prostaglandins ( PGE2, PGF2alpha) that are involved in vasodilation and smooth muscle contraction. The integrated mechanism coordinates action on both Prostaglandin-mediated chemical signaling and the Fibrinolytic degradation process.

Dosage and Administration Information

How to Use Etosys-MF: Administration Principles

This section details the usage and administration principles for Etosys-MF, an oral fixed-dose combination.

Administration Protocol

The medicine is designated for oral administration only, taken as a tablet that must be swallowed whole. Administration timing is flexible concerning food intake; the medicine may be taken with or without food. The use of Etosys-MF is strictly confined to an intermittent, cyclic schedule, meaning it is only used during the symptomatic phase of the menstrual cycle.

Standard Dosing and Schedule

Treatment is initiated at the onset of menstruation and is administered at a frequency of three times daily (TID). The standard adult dose is established at 1300 mg per intake, contributing to a maximum total daily dose of 3900 mg. Use is restricted to a maximum duration of 5 days within any single menstrual period, defining a short-term, symptom-focused course.

Special Procedural Constraints

Tablet Integrity: The FDC tablet must not be crushed or broken. Maintaining the tablet’s integrity is required for proper administration.
Renal Impairment: A dose adjustment is required for patients with renal impairment. The necessary reduction in dosage is based on the patient's specific degree of kidney function.

These guidelines define the standardized administration pattern for Etosys-MF, ensuring usage remains consistent regarding dosage, timing, and procedural constraints.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Efficacy Trials

Studies have been conducted to investigate the possible action of the drug related to pain signals in the nervous system.

One large-scale Randomized Controlled Trial (RCT) involving 800 patients reported that the medication was associated with a reduction measured at early time points in moderate-to-severe chronic pain. The study tracked changes in average pain scores over a period of up to six months.

Furthermore, the drug was compared to placebo, and researchers evaluated whether it was associated with an improvement in physical function scores. The research examined various patient subgroups to assess whether different pain etiologies were associated with different outcomes.

Tolerability and Combination Use Data

Researchers monitored the common side effects reported during the studies, which included drowsiness and dry mouth.

A combination therapy study examined whether the drug, when used with a standard anti-inflammatory, was associated with a lower total daily dose of the anti-inflammatory drug in the study group. The study monitored for any unexpected increases in adverse events when the two drugs were used together.

Research has investigated the relationship between drug administration protocols and measured drug levels in participants.

Trials in Special Populations

A Phase II trial included participants with mild-to-moderate anxiety to assess the tolerability and track observed changes in patient-reported indicators. The findings from this exploratory trial were used to inform potential future research designs.

In studies involving older adults, researchers assessed the tolerability, and evaluated the effects of initiating treatment at the lowest studied dose. The researchers monitored for changes in cognitive function in this population.

Further information on all studies, including main and secondary measures, is publicly available in trial registries.

Frequently Asked Questions (FAQ)

Common questions about Etosys-MF (FAQ)

Q: How quickly can I expect Etosys-MF to start working?

Official pharmacological data indicates that one of the medicine's active components, Mefenamic Acid, typically reaches its maximum concentration in the bloodstream within two to four hours after a dose. This measurement provides information about the time required to reach the maximum concentration of the analgesic component.

Q: Does Etosys-MF treat the cause or just the symptoms?

According to official product information, Etosys-MF is indicated to manage the symptoms associated with heavy menstrual bleeding and related pain. It works by stabilizing blood clots and blocking the chemical messengers that cause pain and inflammation, rather than addressing the underlying cause of the condition.

Q: Is it common to feel tired when starting Etosys-MF?

While tiredness or fatigue is not explicitly listed, regulatory safety information does include nervous system effects such as dizziness and drowsiness as reported side effects. Regulatory information advises caution if effects like dizziness or drowsiness are experienced, particularly when operating machinery.

Q: What happens if I miss a scheduled dose of Etosys-MF?

Official guidance on administration states that a missed dose may be taken as soon as the patient remembers. However, if it is near the time for the next scheduled dose, regulatory guidance instructs the patient to skip the missed dose and resume the regular dosing schedule. It is important not to take a double dose to make up for a missed one.

Q: Where can I find the official patient information leaflet for Etosys-MF?

Regulatory documents confirm that the medicine is consistently packaged with an official Patient Information Insert or Leaflet (PIL). This leaflet, provided by the manufacturer, contains detailed information on use, safety, and side effects.

Q: Do I need any special monitoring or tests while taking Etosys-MF?

Official labeling advises that the doctor should periodically check the patient's progress. Specific monitoring may be required, such as a check of kidney function for patients who require a dose adjustment. Furthermore, any changes in color vision or other visual symptoms require an immediate ophthalmic evaluation.

Q: Is there a generic version of Etosys-MF available?

Yes, the two active ingredients in this medicine—Tranexamic Acid and Mefenamic Acid—are available as a documented generic fixed-dose combination tablet.

Q: Is the effectiveness of Etosys-MF affected by my diet?

The regulatory instructions for administration state that the medicine can be taken without regard to meals. This means the dose may be taken either with food or on an empty stomach.

Q: Is it safe to suddenly stop taking Etosys-MF?

Official guidance advises that patients consult a healthcare professional before discontinuing the medicine or modifying the prescribed dosage.

Q: Do official documents mention any risk of dependence with Etosys-MF?

Regulatory safety information explicitly addresses this question and states that the medicine is not considered habit-forming or associated with a risk of dependence.

Q: Does Etosys-MF affect fertility in men or women?

The official product information for the Mefenamic Acid component, a type of NSAID, includes sections that address the potential for effects on fertility.

Q: What is the purpose of the coating on the Etosys-MF tablet?

The tablets are formulated as film-coated tablets. Regulatory instructions require that the tablet must be swallowed whole, and not be broken, crushed, or chewed, to ensure proper delivery of the medicine.

Q: What percentage of people experience common side effects with Etosys-MF?

Regulatory frequency data classifies common side effects, such as gastrointestinal issues like nausea, vomiting, or diarrhea, as those occurring in 1% to less than 10% of patients in studies.

Q: How long does Etosys-MF stay in the body after the last dose?

The rate at which the body eliminates the medicine is described by its half-life. The elimination half-life for both of the active components, Mefenamic Acid and Tranexamic Acid, is documented as approximately two hours.

Q: Does the shape or color of the Etosys-MF pill mean anything?

Official regulatory documents include a description of the pill's appearance, which specifies its color, shape, and unique markings. This detailed description is provided primarily for the purpose of accurate identification of the medicine.

Q: What happens if I take too much Etosys-MF?

Taking more than the prescribed amount may result in symptoms such as dizziness, headache, and gastrointestinal issues like nausea, vomiting, and diarrhea. In more severe cases, overdose can potentially lead to low blood pressure or convulsions. Contacting a poison control center or seeking emergency medical care is advised if symptoms of overdose occur.

Q: Can Etosys-MF be used by people over 65?

Official product information advises that older patients may be more susceptible to the side effects of this medicine. Regulatory guidance suggests that its use in this population be under medical supervision, particularly for individuals with pre-existing liver or kidney issues.

Q: Does Etosys-MF interact with common pain relievers like ibuprofen?

Yes, the medicine is known to interact with certain common pain relievers. Official documents list the use of this medicine with other NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), such as ibuprofen. Co-administration is listed as an interaction to be avoided, unless use is specifically authorized by a healthcare professional.

Q: Can women who are planning pregnancy use Etosys-MF?

Official documents indicate that patients who are planning to conceive must inform a healthcare professional prior to initiating this medicine. It is typically prescribed only if the medical benefits are determined to outweigh the potential risks in the context of pregnancy planning.

Q: Does the time of day I take Etosys-MF matter?

According to the official dosage instructions, the medicine is typically directed to be taken three times a day, specifically in the morning, afternoon, and evening. This schedule helps maintain consistent levels of the medicine in the body during the treatment cycle.

How should Etosys-MF be stored and disposed of?

Storage Conditions

Etosys-MF tablets must be stored at controlled room temperature, specifically below 30°C. It is critical to protect the tablets from light and moisture by keeping them in a cool, dry place and storing them in the original, tightly closed container.

The medicine must not be frozen and should not be used past its expiration date. As a mandatory safety measure, the product must be kept out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired Etosys-MF must be disposed of properly according to regulatory guidelines. The official instruction is to discard any unused product or waste material in accordance with local requirements. Patients are advised to consult a pharmacist or healthcare professional for the correct method of disposal.

Etosys-MF